Up a level |
Journal Article
Al-Sawaf, O., Bahlo, J., Fischer, K., Herling, C., Hoechstetter, M., Fink, A., von Tresckow, J., Langerbeins, P., Cramer, P., Stilgenbauer, S., Wendtner, C., Eichhorst, B., Hallek, M. and Goede, V. (2017). CHARACTERISTICS, TREATMENT, AND OUTCOMES OF >= 80 YEAR OLD PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) ENROLLED TO PROSPECTIVE TRIALS OF THE GERMAN CLL STUDY GROUP. Haematologica, 102. S. 421 - 422. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Al-Sawaf, O., Bahlo, J., Fischer, K., Herling, C., M., Hochstaetter, Fink, A. M., von Tresckow, J., Langerbeins, P., Cramer, P., Stilgenbauer, S., Wendtner, C. M., Eichhorst, B., Hallek, M. and Goede, V. (2017). Characteristics, treatment, and outcomes of >= 80 year old patients with chronic lymphocytic leukemia (CLL) enrolled to prospective trials of the German CLL study group. Oncol. Res. Treat., 40. S. 139 - 140. BASEL: KARGER. ISSN 2296-5262
Al-Sawaf, O., Kluth, S., Bahlo, J., Hopfinger, G., Fink, A. M., Cramer, P., Maurer, C., Bergmann, M., Dreyling, M., Lange, E., Kneba, M., Stilgenbauer, S., Kiehl, M. G., Jaeger, U., Wendtner, C. M., Fischer, K., Hallek, M. and Eichhorst, B. (2016). Impact of gender on outcome after chemoimmunotherapy with fludarabine, cyclophosphamide and rituximab (FCR) or bendamustin plus R (BR) in CLL patients: a pooled analysis of the German CLL Study Group (GCLLSG). Oncol. Res. Treat., 39. S. 212 - 214. BASEL: KARGER. ISSN 2296-5262
Al-Sawaf, O., Robrecht, S., Bahlo, J., Fink, A. M., Cramer, P., Langerbeins, P., von Tresckow, J., Maurer, C., Kutsch, N., Lange, E., Kiehl, M., Fischer, K., Stilgenbauer, S., Wendtner, C-M, Goede, V, Hallek, M. and Eichhorst, B. (2018). Incidence and outcome of Richter transformation in chronic lymphocytic leukaemia (CLL) - A meta-analysis of German CLL Study Group (GCLLSG) trials. Oncol. Res. Treat., 41. S. 166 - 167. BASEL: KARGER. ISSN 2296-5262
Al-Sawaf, O., Robrecht, S., Bahlo, J., Fink, A. M., Cramer, P., Von Tresckow, J., Lange, E., Kiehl, M., Dreyling, M., Ritgen, M., Duerig, J., Tausch, E., Schneider, C., Stilgenbauer, S., Wendtner, C. M., Fischer, K., Goede, V, Hallek, M. and Eichhorst, B. . Richter transformation in chronic lymphocytic leukemia (CLL)-a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials. Leukemia. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Al-Sawaf, O., Robrecht, S., Bahlo, J., Fink, A. M., Cramer, P., von Tresckow, J., Maurer, C., Bergmann, M., Seiler, T., Lange, E., Kneba, M., Stilgenbauer, S., Doehner, H., Kiehl, M. G., Jaeger, U., Wendtner, C. M., Fischer, K., Goede, V., Hallek, M., Eichhorst, B. and Hopfinger, G. (2017). Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group. Leukemia, 31 (10). S. 2251 - 2255. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Al-Sawaf, O., Robrecht, S., Fink, A., Ritgen, M., Johansson, P., Staber, P., Jaeger, U., Niemann, C., Pallasch, C., Kreuzer, K., Stilgenbauer, S., Fischer, K., Wendtner, C., Hallek, M. and Eichhorst, B. (2020). The CLL-RT1 trial: A multi-center phase-2 trial to evaluate the efficacy and safety of zanubrutinib, a BTK inhibitor, plus tislelizumab, a PD-1 inhibitor, for treatment of patients with Richter Transformation. Oncol. Res. Treat., 43 (SUPPL 4). S. 73 - 74. BASEL: KARGER. ISSN 2296-5262
Bahlo, J., Goede, V, Kutsch, N., Fischer, K., Fink, A. -M, Stilgenbauer, S., Bergmann, M., Eichhorst, B. and Hallek, M. (2016). Evaluation of the international prognostic index for chronic lymphocytic leukemia (CLL-IPI) in elderly patients with comorbidities: Analysis of the CLL11 study population. Oncol. Res. Treat., 39. S. 5 - 7. BASEL: KARGER. ISSN 2296-5262
Bahlo, J., Kutsch, N., Bergmann, M., Byrd, J., Doehner, H., Eichhorst, B., Else, M., Geisler, C., Grever, M., Lepretre, S., Neuberg, D., Oscier, D., Robak, T., Rosenquist, R., Shanafelt, T., Stilgenbauer, S. and Hallek, M. (2015). THE INTERNATIONAL PROGNOSTIC INDEX FOR PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL-IPI)-AN INTERNATIONAL META-ANALYSIS. Haematologica, 100. S. 313 - 315. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Buehler, A., Wendtner, C-M, Kipps, T. J., Rassenti, L., Fraser, G. A. M., Michallet, A-S, Hillmen, P., Duerig, J., Gregory, S. A., Kalaycio, M., Aurran-Schleinitz, T., Trentin, L., Gribben, J. G., Chanan-Khan, A., Purse, B., Zhang, J., De Bedout, S., Mei, J., Hallek, M. and Stilgenbauer, S. (2016). Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. Blood Cancer J., 6. LONDON: NATURE PUBLISHING GROUP. ISSN 2044-5385
Cramer, P., von Tresckow, J., Bahlo, J., Engelke, A., Langerbeins, P., Fink, A. -M., Wesselmann, J. S., Annolleck, T., Pflug, N., Kovacs, G., Fischer, K., Wendtner, C-M, Kreuzer, K. -A., Stilgenbauer, S., Boettcher, S., Eichhorst, B. and Hallek, M. (2015). CLL2-BIG, -BAG, -BCG and -BIO: A series of four phase-II trials evaluating a sequential regimen of combined targeted therapy aiming for a total eradication of MRD in treatment-naive and relapsed/refractory chronic lymphocytic leukemia (CLL). Oncol. Res. Treat., 38. S. 201 - 202. BASEL: KARGER. ISSN 2296-5262
Cramer, P., von Tresckow, J., Bahlo, J., Robrecht, S., Al Sawaf, O., Langerbeins, P., Engelke, A., Fink, A. -M., Fischer, K., Seiler, T., von Weikersthal, L. Fischer, Hebart, H., Kreuzer, K. -A., Ritgen, M., Kneba, M., Wendtner, C. -M., Stilgenbauer, S., Eichhorst, B. and Hallek, M. (2017). BENDAMUSTINE (B), FOLLOWED BY OBINUTUZUMAB (G, GA101) AND VENETOCLAX (A, ABT-199) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2-BAG PHASE-II-TRIAL OF THE GERMAN CLL STUDY GROUP (GCLLSG). Haematologica, 102. S. 171 - 173. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Cramer, P., von Tresckow, J., Bahlo, J., Robrecht, S., Al-Sawaf, O., Langerbeins, P., Engelke, A., Fink, A. -M., Fischer, K., Tausch, E., Seiler, T., von Weikersthal, Fischer L., Hebart, H., Kreuzer, K. -A., Ritgen, M., Kneba, M., Wendtner, C. -M., Stilgenbauer, S., Eichhorst, B. and Hallek, M. (2017). Bendamustine (B), followed by obinutuzumab (G) and venetoclax (A) in patients with chronic lymphocytic leukemia (CLL): CLL2-BAG trial of the German CLL Study Group (GCLLSG). Oncol. Res. Treat., 40. S. 24 - 25. BASEL: KARGER. ISSN 2296-5262
Cramer, P., von Tresckow, J., Bahlo, J., Robrecht, S., Al-Sawaf, O., Langerbeins, P., Fuerstenau, M., Engelke, A., Fink, A. -M, Fischer, K., Kreuzer, K. -A, Ritgen, M., Boettcher, S., Wendtner, C. -M, Stilgenbauer, S., Eichhorst, B. and Hallek, M. (2018). Comparison of 3 different phase II studies using sequential combinations of targeted agents to treat chronic lymphocytic leukemia. Oncol. Res. Treat., 41. S. 29 - 31. BASEL: KARGER. ISSN 2296-5262
Dreger, P., Michallet, M., Bosman, P., Sobh, M., Boumendil, A., Nagler, A., Scheid, C., Cornelissen, J., Mueller, L., Niederwieser, D., Vandenberghe, E., Scortechini, I., Schoemans, H., Andersen, N., Finke, J., Russo, D., Ljungman, P., Passweg, J., van Gelder, M., Durakovic, N., Labussiere, H., Berg, T., Wulf, G., Bethge, W., Stilgenbauer, S., Mordini, N., Schaap, M., Fox, C., Kroeger, N., Montoto, S. and Schetelig, J. (2017). Ibrutinib for bridging to allogeneic hematopoietic stem cell transplantation (alloHCT) in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) is safe and effective: Updated results of a study by the EBMT Chronic Malignancy and Lymphoma Working Parties, the French Cooperative Group for CLL, and the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire (SFGM-TC). Bone Marrow Transplant., 52. S. S99 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Edelmann, J., Haferlach, C., Saub, J., Teleanu, V, Florence, C., Leblonde, V, Delmer, A., Buehler, A., Gribben, J. G., Hallek, M., Doehner, H. and Stilgenbauer, S. (2014). Genomic characterization of primary ultra high-risk and refractory chronic lymphocytic leukemia: Results from the CLL2O trial. Oncol. Res. Treat., 37. S. 220 - 221. BASEL: KARGER. ISSN 2296-5262
Edelmann, J., Tausch, E., Landau, D. A., Robrecht, S., Bahlo, J., Fischer, K., Fink, A. M., Bloehdorn, J., Holzmann, K., Boettcher, S., Werner, L., Kneba, M., Gribben, J. G., Neuberg, D. S., Wu, C. J., Hallek, M., Doehner, H. and Stilgenbauer, S. (2017). Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial. Leukemia, 31 (3). S. 734 - 740. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Elter, T., James, R., Busch, R., Winkler, D., Ritgen, M., Boettcher, S., Kahl, C., Gassmann, W., Stauch, M., Hasan, I., Staib, P., Fischer, K., Fink, A-M, Bahlo, J., Buehler, A., Doehner, H., Wendtner, C-M, Stilgenbauer, S., Engert, A. and Hallek, M. (2012). Fludarabine and cyclophosphamide in combination with alemtuzumab in patients with primary high-risk, relapsed or refractory chronic lymphocytic leukemia. Leukemia, 26 (12). S. 2549 - 2554. LONDON: NATURE PUBLISHING GROUP. ISSN 0887-6924
Estenfelder, S., Tausch, E., Huber, H., Bloehdorn, J., Cymbalista, F., Leblond, V., Delmer, A., Ibach, S., Choquet, S., Dartigeas, C., Cazin, B., Tournilhac, O., Pegourie, B., Seiler, T., Soekler, M., Zirlik, K., Alt, J., Schetelig, J., Hallek, M., Dreger, P., Doehner, H. and Stilgenbauer, S. (2016). MUTATION ANALYSIS BY TARGETED NEXT GENERATION SEQUENCING IN ULTRA HIGH RISK CLL PATIENTS TREATED WITHIN THE CLL2O STUDY. Haematologica, 101. S. 228 - 230. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Ferreri, A. J. M., Cwynarski, K., Pulczynski, E., Fox, C. P., Schorb, E., La Rosee, P., Binder, M., Fabbri, A., Torri, V., Minacapelli, E., Falautano, M., Ilariucci, F., Ambrosetti, A., Roth, A., Hemmaway, C., Johnson, P., Linton, K. M., Pukrop, T., Gorlov, J. S., Balzarotti, M., Hess, G., Keller, U., Stilgenbauer, S., Panse, J., Tucci, A., Orsucci, L., Pisani, F., Levis, A., Krause, S., Schmoll, H. J., Hertenstein, B., Zaccaria, A., Guarini, A., Atta, J., Bassan, R., Cervetti, J., Elter, T., Enggaard, L., Haenel, M., Kneba, M., Liberati, M., Martelli, M., Martens, U., Morra, E., Pinto, A., Zaja, F., Ponzoni, M., Deckert, M., Politi, L. S., Finke, J., Reni, M., Cavalli, F., Zucca, E. and Illerhaus, G. (2017). Autologous stem cell transplantation (ASCT) or whole-brain radiotherapy (WBRT) as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with newly diagnosed primary cns lymphoma (PCNSL): results of the IELSG32 randomized Phase II Trial. Bone Marrow Transplant., 52. S. S96 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Fischer, K., Al-Sawaf, O., Bahlo, J., Fink, A. -M., Tandon, M., Dixon, M., Robrecht, S., Warburton, S., Humphrey, K., Samoylova, O., Liberati, A. M., Pinilla-Ibarz, J., Opat, S., Sivcheva, L., Du, K. Le, Fogliatto, L. M., Niemann, C. U., Weinkove, R., Robinson, S., Kipps, T. J., Boettcher, S., Tausch, E., Humerickhouse, R., Eichhorst, B., Wendtner, C. -M., Langerak, A. W., Kreuzer, K. -A., Ritgen, M., Goede, V., Stilgenbauer, S., Mobasher, M. and Hallek, M. (2019). Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. N. Engl. J. Med., 380 (23). S. 2225 - 2237. WALTHAM: MASSACHUSETTS MEDICAL SOC. ISSN 1533-4406
Fischer, K., Bahlo, J., Fink, A. -M., Busch, R., Boettcher, S., Kreuzer, K. -A., Maurer, C., Mayer, J., Dreger, P., Kneba, M., Doehner, H., Wendtner, C. -M., Stilgenbauer, S., Hallek, M. and Eichhorst, B. (2014). Long Term Remissions After FCR Chemoimmunotherapy In Patients With CLL. Oncol. Res. Treat., 37. S. 86 - 87. BASEL: KARGER. ISSN 2296-5262
Freeman, C. L., Dixon, M., Houghton, R., Kreuzer, K-A, Fingerle-Rowson, G., Herling, M., Humphrey, K., Boettcher, S., de Costa, C. S., Iglesias, V., Stilgenbauer, S., Gribben, J., Hallek, M. and Goede, V. (2016). Role of CD20 expression and other pre-treatment risk factors in the development of infusion-related reactions in patients with CLL treated with obinutuzumab. Leukemia, 30 (8). S. 1763 - 1768. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Fuerstenau, M., Bahlo, J., Fink, A. M., Lange, E., Dreger, P., Dreyling, M., Hess, G., Ritgen, M., Kneba, M., Doehner, H., Stilgenbauer, S., Wendtner, C. M., Goede, V., Fischer, K., Boettcher, S., Hallek, M. and Eichhorst, B. (2020). Residual abdominal lymphadenopathy after intensive frontline chemoimmunotherapy is associated with inferior outcome independently of minimal residual disease status in chronic lymphocytic leukemia. Leukemia, 34 (3). S. 924 - 929. LONDON: SPRINGERNATURE. ISSN 1476-5551
Fuerstenau, M., Fink, A-M, Herling, C., Maurer, C., Kutsch, N., de la Serna, J., Coscia, M., Eckert, R., Crespo, M., Bosch, F., Noesslinger, T., Ghia, P., Kater, A. P., Boettcher, S., Ritgen, M., Schilhabel, A., Stilgenbauer, S., Tausch, E., Fischer, K., Hallek, M. and Eichhorst, B. (2018). B-cell acute lymphoblastic leukemia (B-ALL) in CLL patients treated with lenalidomide. Oncol. Res. Treat., 41. S. 172 - 174. BASEL: KARGER. ISSN 2296-5262
Ghia, P., Coutre, S. E., Furman, R. R., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Hallek, M. J., Coiffier, B., O'Brien, S. M., Stilgenbauer, S., Jiang, W., Jahn, T. M., Wong, M., Lazarov, M. and Sharman, J. P. (2014). EFFECT OF IDELALISIB/RITUXIMAB COMBINATION TREATMENT OF RELAPSED CLL ON THE BCR SIGNALING-RELATED CHEMOKINES CCL3 AND CCL4: DATA FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. Haematologica, 99. S. 56 - 58. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Goede, V., Bahlo, J., Robrecht, S., Al-Sawaf, O., Fink, A. -M., Wendtner, C. -M., Stilgenbauer, S., Fischer, K., Eichhorst, B. and Hallek, M. (2017). CUMULATIVE ILLNESS RATING SCALE PROVIDES PROGNOSTIC INFORMATION BEYOND THE INTERNATIONAL PROGNOSTIC INDEX FOR CHRONIC LYMPHOCYTIC LEUKEMIA: AN ACROSS-TRIAL ANALYSIS BY THE GCLLSG. Haematologica, 102. S. 72 - 73. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Goede, V., Fischer, K., Busch, R., Engelke, A., Eichhorst, B., Wendtner, C. M., Chagorova, T., Dela Serna, J., Dilhuydy, M. S., Opat, S., Owen, C. J., Samoylova, O., Kreuzer, K. A., Langerak, A. W., Ritgen, M., Stilgenbauer, S., Doehner, H., Asikanius, E., Humphrey, K., Wenger, M. K. and Hallek, M. (2014). Obinutuzumab (GA101) plus chlorambucil (Clb) versus rituximab plus Clb in patients with chronic lymphocytic leukaemia (CLL) and comorbidities: recently published results of the CLL11 trial. Br. J. Haematol., 165. S. 19 - 20. HOBOKEN: WILEY-BLACKWELL. ISSN 1365-2141
Hallek, M., Fischer, K., Fingerle-Rowson, G., Fink, A. M., Busch, R., Mayer, J., Hensel, M., Hopfinger, G., Hess, G., von Gruenhagen, U., Bergmann, M., Catalano, J., Zinzani, P. L., Caligaris-Cappio, F., Seymour, J. F., Berrebi, A., Jaeger, U., Cazin, B., Trneny, M., Westermann, A., Wendtner, C. M., Eichhorst, B. F., Staib, P., Buehler, A., Winkler, D., Zenz, T., Boettcher, S., Ritgen, M., Mendila, M., Kneba, M., Doehner, H. and Stilgenbauer, S. (2010). Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet, 376 (9747). S. 1164 - 1175. NEW YORK: ELSEVIER SCIENCE INC. ISSN 0140-6736
Hoechstetter, M. A., Busch, R., Eichhorst, B., Buehler, A., Winkler, D., Bahlo, J., Eckart, M. J., Vehling-Kaiser, U., Schimke, H., Jaeger, U., Hurtz, H. J., Hopfinger, G., Hartmann, F., Fuss, H., Abenhardt, W., Blau, I., Freier, W., Mueller, L., Goebeler, M., Wendtner, C. M., Fischer, K., Bentz, M., Emmerich, B., Doehner, H., Hallek, M. and Stilgenbauer, S. (2017). A new prognostic model based on clinical, biological and genetic parameters improves prognostication in early stage CLL patients: results of the prospective CLL1 trial of the German CLL study group. Oncol. Res. Treat., 40. S. 25 - 27. BASEL: KARGER. ISSN 2296-5262
Hoechstetter, M. A., Busch, R., Eichhorst, B., Buehler, A., Winkler, D., Eckart, M. J., Vehling-Kaiser, U., Schimke, H., Jaeger, U., Hurtz, H. J., Hopfinger, G., Hartmann, F., Fuss, H., Abenhardt, W., Blau, I., Freier, W., Mueller, L., Goebeler, M., Wendtner, C. M., Bahlo, J., Fischer, K., Bentz, M., Emmerich, B., Doehner, H., Hallek, M. and Stilgenbauer, S. (2017). Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group. Leukemia, 31 (12). S. 2833 - 2838. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Klymenko, T., Bloehdorn, J., Bahlo, J., Robrecht, S., Akylzhanova, G., Cox, K., Estenfelder, S., Wang, J., Edelmann, J., Strefford, J. C., Wojdacz, T. K., Fischer, K., Hallek, M., Stilgenbauer, S., Cragg, M., Gribben, J. and Braun, A. (2018). Lamin B1 regulates somatic mutations and progression of B-cell malignancies. Leukemia, 32 (2). S. 364 - 376. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Klymenko, T., Bloehdorn, J., Bahlo, J., Robrecht, S., Wang, J., Fischer, K., Akylzhanova, G., Edelmann, J., Estenfelder, S., Strefford, J., Wojdacz, T., Hallek, M., Stilgenbauer, S., Cragg, M., Gribben, J. and Braun, A. (2017). NUCLEAR LAMINA REGULATES SOMATIC HYPERMUTATION AND PROGRESSION OF B CELL MALIGNANCIES. Haematologica, 102. S. 228 - 229. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Knittel, G., Korovkina, D., Liedgens, P., Rehkaemper, T., Fritz, C., Torgovnick, A., Al-Baldawi, Y., Al-Maarri, M., Cun, Y., Fedorchenko, O., Riabinska, A., Beleggia, F., Nguyen, P. -H., Wunderlich, F. T., Ortmann, M., Montesinos-Rongen, M., Tausch, E., Stilgenbauer, S., Frenzel, L., Herling, M., Herling, C., Bahlo, J., Hallek, M., Peifer, M., Buettner, R., Persigehl, T. and Reinhardt, H. C. (2017). Novel models of high-risk CLL reveal an actionable PARP1 dependence in ATM-defective CLL in vivo. Oncol. Res. Treat., 40. S. 27 - 28. BASEL: KARGER. ISSN 2296-5262
Kovacs, G., Bahlo, J., Kluth, S., Fink, A. M., Cramer, P., von Tresckow, J., Maurer, C., Langerbeins, P., Gross-Opphoff-Mueller, C., Fischer, K., Wendtner, C. -M., Kreuzer, K. -A., Stilgenbauer, S., Hallek, M., Eichhorst, B. and Goede, V. (2015). Impact and predictors of reducing prescribed doses of fludarabine, cyclophosphamide and rituximab (FCR) in frontline treatment of chronic lymphocytic leukemia (CLL). Oncol. Res. Treat., 38. S. 91 - 92. BASEL: KARGER. ISSN 2296-5262
Kraemer, I., Stilgenbauer, S., Dietrich, S., Boettcher, S., Bunjes, D. W., Zeis, M., Stadler, M., Bittenbring, J. T., Uharek, L., Scheid, C., Hegenbart, U., Ho, A., Anthony, D., Hallek, M., Kneba, M., Schmitz, N., Doehner, H. and Dreger, P. (2017). Long-term outcome of allogeneic hematopoietic stem cell transplantation (HSCT) for chronic lymphocytic leukemia (CLL): 10-year follow-up of the GCLLSG CLL3X trial. Bone Marrow Transplant., 52. S. S424 - 1. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5365
Kutsch, N., Goede, V, Robrecht, S., Kelma, F., Bahlo, J., Fischer, K., Fink, A. -M, Schlag, R., Lange, E., Weide, R., Dreyling, M., Jaeger, U., Stilgenbauer, S., Doehner, H., Kneba, M., Ritgen, M., Wendtner, C. -M, Hallek, M. and Eichhorst, B. (2018). Treatment response and health-related quality of life during management of chronic lymphocytic leukemia (CLL) - a metaanalysis of 3 phase III studies of the German CLL Study Group (GCLLSG). Oncol. Res. Treat., 41. S. 30 - 31. BASEL: KARGER. ISSN 2296-5262
Langerbeins, P., Busch, R., Schweighofer, C. D., Mueller, C., Cramer, P., Fink, A. M., Faetkenheuer, G., Hartmann, P., Stilgenbauer, S., Boettcher, S., Wendtner, C. M., Hallek, M. and Eichhorst, B. (2014). SEVERE INFECTIONS ARE MORE COMMON IN PHYSICALLY FIT CLL PATIENTS WITH FCR-THERAPY COMPARED TO BR: RESULTS OF THE INTERMIN-ANALYSIS OF THE CLL10 TRIAL OF THE GERMAN CLL STUDY GROUP. Haematologica, 99. S. 55 - 57. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Langerbeins, P., Busch, R., Schweighofer, C. D., Mueller, C., Fischer, K., Fink, A. -M., Cramer, P., Faetkenheuer, G., Hartmann, P., Stilgenbauer, S., Boettcher, S., Wendtner, C. -M., Hallek, M. and Eichhorst, B. (2014). More severe infectious complications in CLL patients treated with fludarabine, cyclophosphamide, rituximab (FCR) in comparison to bendamustin plus rituximab (BR): Results of the interim-analysis of the CLL10 trial of the German CLL Study Group. Oncol. Res. Treat., 37. S. 185 - 186. BASEL: KARGER. ISSN 2296-5262
Loeschcke, K., Fink, A., Bahlo, J., Westermann, A., Zey, A., Fischer, K., Wendtner, C. M., Noesslinger, T., Ghia, P., Bosch, F., Kater, A. P., Kreuzer, K. A., Stilgenbauer, S., Boettcher, S., Eichhorst, B. and Hallek, M. (2014). CENTRAL SCREENING ENABLES IDENTIFICATION OF HIGH RISK CLL PATIETNS FOR LENALIDOMIDE MAINTENANCE THERAPY WITHIN THE CLLM1 TRIAL OF THE GERMAN CLL STUDY GROUP. Haematologica, 99. S. 587 - 589. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Lohmann, G., Vasyutina, E., Bloehdorn, J., Reinart, N., Schneider, J. I., Babu, V., Knittel, G., Crispatzu, G., Mayer, P., Prinz, C., Muenzner, J. K., Biersack, B., Efremov, D. G., Chessa, L., Herling, C. D., Stilgenbauer, S., Hallek, M., Schobert, R., Reinhardt, H. C., Schumacher, B. and Herling, M. (2017). Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemia. Leukemia, 31 (5). S. 1177 - 1187. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Maurer, C., Langerbeins, P., Bahlo, J., Cramer, P., Fink, A. M., Pflug, N., Engelke, A., von Tresckow, J., Kovacs, G., Stilgenbauer, S., Wendtner, C-M, Mueller, L., Ritgen, M., Seiler, T., Fischer, K., Hallek, M. and Eichhorst, B. (2016). Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL. Leukemia, 30 (10). S. 2019 - 2026. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Mueller, C., Cymbalista, F., Schweighofer, C., Busch, R., Porcher, R., Langerbeins, P., Cazin, B., Fink, A. -M., Dreyfus, B., Ibach, S., Lepretre, S., Fischer, K., Vehling-Kaiser, U., Eichhorst, B., Bergmann, M. A., Wendtner, C. -M., Stilgenbauer, S., Doehner, H., Leblond, V., Hallek, M. and Levy, V. (2014). Early versus deferred treatment with combined fludarabine, cyclophosphamide and rituximab (FCR) improves event-free survival in patients with high-risk Binet stage A chronic lymphocytic leukemia (CLL). Oncol. Res. Treat., 37. S. 184 - 185. BASEL: KARGER. ISSN 2296-5262
Munir, T., Hillmen, P., Sharman, J., Coutre, S., Furman, R., Cheson, B., Pagel, J., Barrientos, J., Zelenetz, A., Kipps, T., Flinn, I., Ghia, P., Hallek, M., Coiffier, B., O'Brien, S., Tausch, E., Kreuzer, K., Jiang, W., Lazarov, M., Li, D., Jahn, T. and Stilgenbauer, S. (2015). Second interim analysis of a phase 3 study of idelalisib plus rituximab (R) for relapsed chronic lymphocytic leukaemia (CLL): efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factors. Br. J. Haematol., 169. S. 19 - 20. HOBOKEN: WILEY-BLACKWELL. ISSN 1365-2141
Munir, T., Hillmen, P., Sharman, J., Coutre, S., Furman, R., Cheson, B., Pagel, J., Barrientos, J., Zelenetz, A., Kipps, T., Flinn, I., Ghia, P., Hallek, M., Coiffier, B., O'Brien, S., Tausch, E., Kreuzer, K., Jiang, W., Lazarov, M., Li, D., Jahn, T. and Stilgenbauer, S. (2015). Second interim analysis of a phase 3 study of idelalisib plus rituximab (R) for relapsed chronic lymphocytic leukaemia (CLL): efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factors. Br. J. Haematol., 169. S. 19 - 20. HOBOKEN: WILEY-BLACKWELL. ISSN 1365-2141
Munir, T., O'Brien, S., Jones, J. A., Coutre, S. E., Mato, A. R., Hillmen, P., Tam, C., Osterborg, A., Siddiqi, T., Thirman, M. J., Furman, R. R., Ilhan, O., Keating, M., Call, T. G., Brown, J. R., Stevens-Brogan, M., Li, Y., Clow, F., James, D., Chu, A., Hallek, M. and Stilgenbauer, S. (2015). Results from the phase 2 RESONATE (TM)-17 Trial: Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic leukaemia with 17p deletion. Br. J. Haematol., 169. S. 71 - 72. HOBOKEN: WILEY. ISSN 1365-2141
Munir, T., O'Brien, S., Jones, J. A., Coutre, S. E., Mato, A. R., Hillmen, P., Tam, C., Osterborg, A., Siddiqi, T., Thirman, M. J., Furman, R. R., Ilhan, O., Keating, M., Call, T. G., Brown, J. R., Stevens-Brogan, M., Li, Y., Clow, F., James, D., Chu, A., Hallek, M. and Stilgenbauer, S. (2015). Results from the phase 2 RESONATE (TM)-17 Trial: Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic leukaemia with 17p deletion. Br. J. Haematol., 169. S. 71 - 72. HOBOKEN: WILEY. ISSN 1365-2141
Oberbeck, S., Schrader, A., Warner, K., Jungherz, D., Crispatzu, G., von Jan, J., Chmielewski, M., Ianevski, A., Diebner, H. H., Mayer, P., Ados, A. Kondo, Wahnschaffe, L., Braun, T., Mueller, T. A., Wagle, P., Bouska, A., Neumann, T., Puetzer, S., Varghese, L., Pflug, N., Thelen, M., Makalowski, J., Riet, N., Goex, H. J. M., Rappl, G., Altmueller, J., Kotrova, M., Persigehl, T., Hopfinger, G., Hansmann, M. L., Schloesser, H., Stilgenbauer, S., Duerig, J., Mougiakakos, D., Von Bergwelt-Baildon, M., Roeder, I, Hartmann, S., Hallek, M., Moriggl, R., Brueggemann, M., Aittokallio, T., Iqbal, J., Newrzela, S., Abken, H. and Herling, M. (2020). Noncanonical effector functions of the T-memory-like T-PLL cell are shaped by cooperative TCL1A and TCR signaling. Blood, 136 (24). S. 2786 - 2803. WASHINGTON: AMER SOC HEMATOLOGY. ISSN 1528-0020
Pflug, N., Maurer, C., Bahlo, J., Kluth, S., Rhein, C., Cramer, P., Gross-Ophoff, C., Langerbeins, P., Fink, A. -M., Eichhorst, B., Kreuzer, K. -A., Tausch, E., Stilgenbauer, S., Boettcher, S., Doehner, H., Kneba, M., Hallek, M., Wendtner, C. -M., Bergmann, M. and Fischer, K. (2015). Bendamustine and Rituximab in combination with Lenalidomide in patients with relapsed or refractory and in patients with previously untreated chronic lymphocytic leukemia: A multicenter phase I/II safety and efficacy trial of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG). Oncol. Res. Treat., 38. S. 92 - 93. BASEL: KARGER. ISSN 2296-5262
Ritgen, M., Langerak, A., Goede, V., Bahlo, J., Kluth, S., Fischer, K., Steurer, M., Trneny, M., Mulligan, S., Mey, U., Trunzer, K., Humphrey, K., Fingerle-Rowson, G., Stilgenbauer, S., Boettcher, S., Bruggemann, M., Hallek, M., Kneba, M. and van Dongen, J. (2016). QUANTITATIVE MRD IS PROGNOSTIC FOR PROGRESSION-FREE & OVERALL SURVIVAL IN ELDERLY PATIENTS RECEIVING CHLORAMBUCIL ALONE OR WITH OBINUTUZUMAB/RITUXIMAB: A PROSPECTIVE ANALYSIS OF THE GCLLSG CLL11 STUDY. Haematologica, 101. S. 149 - 151. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Schrader, A., Crispatzu, G., Oberbeck, S., Mayer, P., Putzer, S., von Jan, J., Vasyutina, E., Warner, K., Weit, N., Pflug, N., Braun, T., Andersson, E. I., Yadav, B., Riabinska, A., Maurer, B., Ferreira, M. S. Ventura, Beier, F., Altmueller, J., Lanasa, M., Herling, C. D., Haferlach, T., Stilgenbauer, S., Hopfinger, G., Peifer, M., Bruemmendorf, T. H., Nuernberg, P., Elenitoba-Johnson, K. S. J., Zha, S., Hallek, M., Moriggl, R., Reinhardt, H. C., Stern, M. -H., Mustjoki, S., Newrzela, S., Frommolt, P. and Herling, M. (2018). Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL. Nat. Commun., 9. LONDON: NATURE PUBLISHING GROUP. ISSN 2041-1723
Sharman, J., Coutre, S., Furman, R., Cheson, B., Pagel, J., Hillmen, P., Barrientos, J., Zelenetz, A., Kipps, T., Flinn, I., Ghia, P., Hallek, M., Coiffier, B., O'Brien, S. and Stilgenbauer, S. (2014). EFFICACY OF IDELALISIB IN CLL SUBPOPULATIONS HARBORING DEL(17P) AND OTHER ADVERSE PROGNOSTIC FACTORS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. Leuk. Res., 38. S. S44 - 2. OXFORD: PERGAMON-ELSEVIER SCIENCE LTD. ISSN 0145-2126
Shehata, M., Demirtas, D., Schnabl, S., Hilgarth, M., Hubmann, R., Fonatsch, C., Schwarzinger, I., Hopfinger, G., Eigenberger, K., Heintel, D., Porpaczy, E., Vanura, K., Hauswirth, A., Schwarzmeier, J. D., Gaiger, A., Stilgenbauer, S., Hallek, M., Bilban, M. and Jaeger, U. (2010). Sequential gene expression profiling during treatment for identification of predictive markers and novel therapeutic targets in chronic lymphocytic leukemia. Leukemia, 24 (12). S. 2122 - 2128. LONDON: NATURE PUBLISHING GROUP. ISSN 0887-6924
Soumerai, J. D., Barrientos, J. C., Hallek, M., Kipps, T. J., Jones, J. A., Xing, G., Yao, N. S., Ysebaert, L., Stilgenbauer, S. and Zelenetz, A. D. (2016). AN EVALUATION OF THE CLL-IPI SCORE AND COMPREHENSIVE PROGNOSTIC FACTOR ANALYSIS IN PATIENTS WITH R/R CLL IN IDELALISIB PHASE 3 RANDOMIZED STUDIES. Haematologica, 101. S. 53 - 55. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Stilgenbauer, S., Chyla, B., Eichhorst, B., Schetelig, J., Munir, T., Hillmen, P., Seymour, J. F., Roberts, A. W., Coutre, S., Jurczak, W., Mulligan, S. P., Puvvada, S., Wendtner, C-M, Davids, M., Boeettcher, S., Cerri, E., Zhou, L., Popovic, R., Poteracki, M., Arzt, J., Kim, S. Y., Verdugo, M., Bhathena, A., Wierda, W. and Hallek, M. (2017). VENETOCLAX IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION: OUTCOME AND MINIMAL RESIDUAL DISEASE FROM THE FULL POPULATION OF THE PIVOTAL M13-982 TRIAL. Haematologica, 102. S. 311 - 313. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Stilgenbauer, S., Coutre, S. E., Furman, R. R., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I. W., Ghia, P., Hallek, M. J., Coiffier, B., O'Brien, S. M., Tausch, E., Kreuzer, K. A., Jiang, W., Jahn, T. M., Lazarov, M. and Sharman, J. P. (2014). EFFICACY OF IDELALISIB IN CLL SUBPOPULATIONS HARBORING DEL(17P) AND OTHER ADVERSE PROGNOSTIC FACTORS: RESULTS FROM A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL. Haematologica, 99. S. 521 - 522. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Stilgenbauer, S., Hallek, M. J., Coutre, S. E., Furman, R. R., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I, Ghia, P., Coiffier, B., O'Brien, S. M., Tausch, E., Sharman, J. P., Ruppert, S., Schuster, A. and Kroenig, H. (2014). Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial. Oncol. Res. Treat., 37. S. 184 - 185. BASEL: KARGER. ISSN 2296-5262
Stilgenbauer, S., Jones, J. A., Coutre, S. E., Mato, A. R., Hillmen, P., Tam, C., Osterborg, A., Siddiqi, T., Thirman, M. J., Furman, R. R., Ilhan, O., Keating, M., Call, T. G., Brown, J. R., Stevens-Brogan, M., Li, Y., Clow, F., James, D. F., Chu, A. D., Hallek, M. and O'Brien, S. (2015). Results from the phase 2 RESONATE (TM)-17 trial: Efficacy and safety of Ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma with Del17p. Oncol. Res. Treat., 38. S. 92 - 93. BASEL: KARGER. ISSN 2296-5262
Stilgenbauer, S., Schleinitz, T. Aurran, Hallek, M., Lang, F., Offner, F., Rossi, J. -F., Schroyens, W., Van Den Neste, E., Ysebaert, L., Blum, P., Hocke, J., Kress, U. U. and Zenz, T. (2015). PHASE I, FIRST-IN-HUMAN TRIAL OF BI 836826 (AN ANTI-CD37 ANTIBODY) IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). Haematologica, 100. S. 225 - 227. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Tausch, E., Landau, D., Taylor-Weiner, A., Stewart, C., Reiter, J., Bahlo, J., Kluth, S., Bozic, I., Lawrence, M., Boettcher, S., Cibulskis, K., Mertens, D., Sougnez, C., Rosenberg, M., Hess, J., Carter, S., Edelmann, J., Kless, S., Fink, A., Fischer, K., Ritgen, M., Kneba, M., Gabriel, S., Lander, E., Nowak, M., Doehner, H., Hallek, M., Neuberg, D., Getz, G., Stilgenbauer, S. and Wu, C. (2015). WHOLE EXOME SEQUENCING OF 278 CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS FROM THE CLL8 TRIAL UNCOVERS DRIVER MUTATIONS WITH CLINICAL IMPACT AND THEIR EVOLUTIONARY HISTORY IN CANCER PATHOGENESIS. Haematologica, 100. S. 335 - 337. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Thurner, L., Held, G., Poeschel, V, Berdel, C., Ott, G., Schmidt, C., Viardot, A., Engel-Riedel, W., Borchmann, P., Shpilberg, O., Witzens-Harig, M., Frickhofen, N., Nickelsen, M., Griesinger, F., Krammer-Steiner, B., Neubauer, A., Federico, M., Brown, de Nully P., Stilgenbauer, S., Murawski, N., Altmann, B., Truemper, L., Schmidberger, H., Ruebe, C., Fleckenstein, J., Schmitz, N., Loeffler, M. and Ziepert, M. (2020). Role of radiotherapy and dose-densification of R-CHOP in primary mediastinal B-cell lymphoma: a subgroup analysis of the unfolder trial of the German Lymphoma Alliance (GLA). Oncol. Res. Treat., 43 (SUPPL 4). S. 61 - 62. BASEL: KARGER. ISSN 2296-5262
Tiao, G., Improgo, M. R., Kasar, S., Poh, W., Kamburov, A., Landau, D-A, Tausch, E., Taylor-Weiner, A., Cibulskis, C., Bahl, S., Fernandes, S. M., Hoang, K., Rheinbay, E., Kim, H. T., Bahlo, J., Robrecht, S., Fischer, K., Hallek, M., Gabriel, S., Lander, E. S., Stilgenbauer, S., Wu, C. J., Kiezun, A., Getz, G. and Brown, J. R. (2017). Rare germline variants in ATM are associated with chronic lymphocytic leukemia. Leukemia, 31 (10). S. 2244 - 2248. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Tiao, G., Improgo, M. R., Kasar, S., Poh, W., Kamburov, A., Landau, D. -A., Tausch, E., Taylor-Weiner, A., Cibulskis, C., Bahl, S., Fernandes, S. M., Hoang, K., Rheinbay, E., Kim, H. T., Bahlo, J., Robrecht, S., Fischer, K., Hallek, M., Gabriel, S., Lander, E., Stilgenbauer, S., Wu, C., Kiezun, A., Getz, G. and Brown, J. (2017). GERMLINE RARE VARIANT ASSOCIATION ANALYSIS IN CHRONIC LYMPHOCYTIC LEUKEMIA. Haematologica, 102. S. 65 - 66. PAVIA: FERRATA STORTI FOUNDATION. ISSN 0390-6078
Vasyutina, E., Boucas, J. M., Bloehdorn, J., Aszyk, C., Crispatzu, G., Stiefelhagen, M., Breuer, A., Mayer, P., Lengerke, C., Doehner, H., Beutner, D., Rosenwald, A., Stilgenbauer, S., Hallek, M., Benner, A. and Herling, M. (2015). The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL. Leukemia, 29 (10). S. 2003 - 2015. LONDON: NATURE PUBLISHING GROUP. ISSN 1476-5551
Westermann, A., Fink, A., Zey, A., Wesselmann, J. S., Busch, R., Fischer, K., Wendtner, C., Kreuzer, K-A, Stilgenbauer, S., Boettcher, S., Eichhorst, B. and Hallek, M. (2014). Screening supported by a central review allows a precise selection of the population for maintenance therapy within the CLLM1 trial of the German CLL Study Group. Oncol. Res. Treat., 37. S. 85 - 86. BASEL: KARGER. ISSN 2296-5262
Zenz, T., Vollmer, D., Trbusek, M., Smardova, J., Benner, A., Soussi, T., Helfrich, H., Heuberger, M., Hoth, P., Fuge, M., Denzel, T., Haebe, S., Malcikova, J., Kuglik, P., Truong, S., Patten, N., Wu, L., Oscier, D., Ibbotson, R., Gardiner, A., Tracy, I., Lin, K., Pettitt, A., Pospisilova, S., Mayer, J., Hallek, M., Doehner, H. and Stilgenbauer, S. (2010). TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations. Leukemia, 24 (12). S. 2072 - 2080. LONDON: NATURE PUBLISHING GROUP. ISSN 0887-6924
von Tresckow, J., Cramer, P., Bahlo, J., Engelke, A., Langerbeins, P., Fink, A. -M, Klaproth, H., Tausch, E., Fischer, K., Wendtner, C-M, Kreuzer, K. -A, Stilgenbauer, S., Boettcher, S., Eichhorst, B. and Hallek, M. (2016). CLL2-BIG - a sequential treatment regimen of Bendamustine followed by GA101 and Ibrutinib followed by Ibrutinib and GA101 maintenance in patients with Chronic Lymphocytic Leukemia (CLL): Interim results of a phase II-trial by the German CLL Study Group. Oncol. Res. Treat., 39. S. 121 - 122. BASEL: KARGER. ISSN 2296-5262
von Tresckow, J., Cramer, P., Bahlo, J., Engelke, A., Langerbeins, P., Fink, A. -M., Klaproth, H., Tausch, E., Fischer, K., Wendtner, C. -M., Kreuzer, K. -A., Stilgenbauer, S., Boettcher, S., Eichhorst, B. and Hallek, M. (2016). CLL2-BIG - a Novel Treatment Regimen of Bendamustine Followed By GA101 and Ibrutinib Followed By Ibrutinib and GA101 Maintenance in Patients with Chronic Lymphocytic Leukemia (CLL): Interim Results of a Phase II-Trial. Oncol. Res. Treat., 39. S. 117 - 119. BASEL: KARGER. ISSN 2296-5262